Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × ALK+ Advanced NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 525 Neoplasms 266 Prostatic Neoplasms 241 Carcinoma, Non-Small-Cell Lung 240 Colorectal Neoplasms 189 Multiple Myeloma 161 Neoplasm Metastasis 129 Lung Neoplasms 125 Lymphoma 106 Leukemia, Myeloid, Acute 106 Leukemia 105 Lymphoma, Follicular 101 Lymphoma, Non-Hodgkin 91 Stomach Neoplasms 90 Rectal Neoplasms 84 Ovarian Neoplasms 84 Colonic Neoplasms 84 Precursor Cell Lymphoblastic Leukemia-Lymphoma 83 Uterine Cervical Neoplasms 81 Head and Neck Neoplasms 81 Carcinoma, Hepatocellular 78 Pain 77 Leukemia, Lymphocytic, Chronic, B-Cell 77 Pancreatic Neoplasms 76 Melanoma 69 Lymphoma, Large B-Cell, Diffuse 64 Papillomavirus Infections 63 Recurrence 59 Squamous Cell Carcinoma of Head and Neck 56 Brain Neoplasms 56

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡